Sustainable Global Health Systems and Pharmaceutical Development
Despite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development. For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical eleme...
Sparad:
| Huvudupphovsman: | |
|---|---|
| Institutionell upphovsman: | |
| Materialtyp: | Elektronisk E-bok |
| Språk: | engelska |
| Publicerad: |
Cham :
Springer International Publishing : Imprint: Springer,
2024.
|
| Upplaga: | 1st ed. 2024. |
| Serie: | AAPS Advances in the Pharmaceutical Sciences Series,
60 |
| Ämnen: | |
| Länkar: | https://doi.org/10.1007/978-3-031-50415-0 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-50415-0 | ||
| 003 | DE-He213 | ||
| 005 | 20251202165455.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 240903s2024 sz | s |||| 0|eng d | ||
| 020 | |a 9783031504150 |9 978-3-031-50415-0 | ||
| 024 | 7 | |a 10.1007/978-3-031-50415-0 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 0 | 4 | |a 615 |2 23 |
| 100 | 1 | |a Mittal, Bhavishya. |e author. |0 (orcid)0000-0002-4222-0816 |1 https://orcid.org/0000-0002-4222-0816 |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 245 | 1 | 0 | |a Sustainable Global Health Systems and Pharmaceutical Development |h [electronic resource] / |c by Bhavishya Mittal. |
| 250 | |a 1st ed. 2024. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2024. | |
| 300 | |a XXIX, 247 p. 109 illus., 92 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a AAPS Advances in the Pharmaceutical Sciences Series, |x 2210-738X ; |v 60 | |
| 505 | 0 | |a Health Care Industry -- Reimbursement and Pricing -- Current Stage of Pharmaceutical Development -- Desired Future State of Pharmaceutical Development -- Case Studies I -- Case Studies II -- Case Studies III. | |
| 520 | |a Despite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development. For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical elements and a few strategic elements. However, there is minimal integration of financial valuation elements (commonly employed in other high tech industries such as fine chemicals, automotive, aerospace, etc.) into pharmaceutical drug development. Unfortunately, this hurts the sustainability of the health system of which these products will be a part in the future. A desirable future state is the one that integrates fundamentals of economics in product design and development so that the decision-making is parameterized, the cost of goods could be lowered, wastage can be reduced, patient-centricity is built into the design, and manufacturing/distribution efficiencies can be gained. The financial benefits of such an approach could allow for these savings to be passed on to the stakeholders and improve the value proposition of pharmaceuticals, which is critical to maintaining the innovation potential. This book hopes to introduce the reader to this desired future state of pharmaceutical drug development. . | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Pharmacy. | |
| 650 | 0 | |a Public health. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Epidemiology. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Pharmacy. |
| 650 | 2 | 4 | |a Public Health. |
| 650 | 2 | 4 | |a Pharmaceutics. |
| 650 | 2 | 4 | |a Epidemiology. |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031504143 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031504167 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031504174 |
| 830 | 0 | |a AAPS Advances in the Pharmaceutical Sciences Series, |x 2210-738X ; |v 60 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-50415-0 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||